DOI QR코드

DOI QR Code

Low-intensity extracorporeal shock wave therapy ameliorates fibrosis and renal function in a preclinical model of chronic kidney disease

  • Ji-Hyun Moon (Department of Anatomy, College of Medicine, Konyang University) ;
  • Ah La Choi (Department of Anatomy, College of Medicine, Konyang University) ;
  • Hye Jeong Ahn (Department of Anatomy, College of Medicine, Konyang University) ;
  • Nam Seob Lee (Department of Anatomy, College of Medicine, Konyang University) ;
  • Young Gil Jeong (Department of Anatomy, College of Medicine, Konyang University) ;
  • Jaeku Kang (Department of Pharmacology, College of Medicine, Konyang University) ;
  • Min-Jeong Choi (Department of Medicine, Konyang University) ;
  • Jin-Kyoung Hong (Department of Medicine, Konyang University) ;
  • Seung Yun Han (Department of Anatomy, College of Medicine, Konyang University)
  • 투고 : 2026.01.05
  • 심사 : 2026.01.31
  • 발행 : 2026.06.30

초록

This study investigates the potential therapeutic effects of low-intensity extracorporeal shock wave therapy (Li-ESWT) in the treatment of chronic kidney disease (CKD) using a preclinical mice model, which was established by high adenine diet. Four experimental groups were formed: normal (NL), NL+Li-ESWT (NL+ESWT), CKD, and CKD+Li-ESWT (CKD+ESWT), and received appropriate interventions over a period of 3 weeks. Immunohistochemistry analysis revealed significant upregulation of HSP70 expression, a marker for cells affected by mechanical stimulus, in the NL+ESWT group, confirming successful delivery of Li-ESWT to kidney tissues. Body weight, kidney weight, blood urea nitrogen (BUN), and creatinine values showed no significant differences between the NL and NL+ESWT groups, indicating that Li-ESWT alone did not affect these parameters. However, in the CKD+ESWT group, although kidney weight did not significantly differ from the CKD group, both body weight and renal function parameters showed marked improvement compared to the CKD group, suggesting a positive impact of Li-ESWT on general condition and renal function in CKD. The following histological examination showed that the CKD+ESWT group exhibited significantly reduced tubulointerstitial injury and fibrosis compared to the CKD group, further supporting the therapeutic potential of Li-ESWT in CKD management. To reveal potential modulation of ESWT on the upstream of fibrosis, fibrosis-related gene expressions, i.e., Acta2, Col1a1, Col3a1, and Fn1, were examined. The results demonstrated a significant reduction in the expression of fibrosis-related genes in the CKD+ESWT group compared to the CKD group, highlighting the molecular effects of Li-ESWT in mitigating CKD-associated fibrosis.

키워드

과제정보

This research was funded by the National Research Foundation, Korea (#RS-2023-00251456). This research was also supported by the Regional Innovation System & Education (RISE) program through the Daejeon RISE Center, funded by the Ministry of Education (MOE) and the Daejeon, Korea (#2025-RISE-06-001).

참고문헌

  1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022;12:7-11. https://doi.org/10.1016/j.kisu.2021.11.003
  2. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Massy Z, Wanner C, Anders HJ. Chronic kidney disease. Nat Rev Dis Primers 2017;3:17088. https://doi.org/10.1038/nrdp.2017.88
  3. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, RodriguesDiez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol 2020;16:269-88. https://doi.org/10.1038/s41581-019-0248-y
  4. Wang L, He Y, Han C, Zhu P, Zhou Y, Tang R, He W. Global burden of chronic kidney disease and risk factors, 1990-2021: an update from the global burden of disease study 2021. Front Public Health 2025;13:1542329. https://doi.org/10.3389/fpubh.2025.1542329
  5. Schnaper HW. The tubulointerstitial pathophysiology of progressive kidney disease. Adv Chronic Kidney Dis 2017;24:107-16. https://doi.org/10.1053/j.ackd.2016.11.011
  6. Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol 2018;80:309-26. https://doi.org/10.1146/physiol.2018.80.issue-1
  7. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
  8. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21:1819-34. https://doi.org/10.1681/ASN.2010080793
  9. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013;19:1047-53. https://doi.org/10.1038/nm.3218
  10. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 2014;124:2299-306. https://doi.org/10.1172/JCI72267
  11. Wang CJ. Extracorporeal shockwave therapy in musculoskeletal disorders. J Orthop Surg Res 2012;7:11. https://doi.org/10.1186/1749-799X-7-11
  12. Skov-Jeppesen SM, Petersen NA, Yderstraede KB, Jensen BL, Bistrup C, Lund L. Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) in renal diseases: a review of animal and human studies. Int J Nephrol Renovasc Dis 2023;16:31-42.
  13. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. National Academies Press; 2011.
  14. Yoshida M, Nakamichi T, Mori T, Ito K, Shimokawa H, Ito S. Low-energy extracorporeal shock wave ameliorates ischemic acute kidney injury in rats. Clin Exp Nephrol 2019;23:597-605. https://doi.org/10.1007/s10157-019-01689-7
  15. French BW, Breidenbach JD, Yassine SG, Khatib-Shahidi BZ, Kazmi S, Murphy CM, Bashir HS, Benson EM, Timalsina B, Shrestha U, Faleel D, Boyapalli S, Dube P, Lad A, Syed I, Malhotra D, Gohara A, Kennedy DJ, Haller ST. A simplified model of adenine-induced chronic kidney disease using SKH1 mice. Cells 2024;13:2117.
  16. Sarica K, Sari I, Erbagci A, Yagci F, Yurtseven C, Karakok M. Evaluation of heat shock protein 70 expression in renal parenchyma subjected to shockwave lithotripsy. J Endourol 2003;17:805-8. https://doi.org/10.1089/089277903770802425
  17. Zhang X, Krier JD, Amador Carrascal C, Greenleaf JF, Ebrahimi B, Hedayat AF, Textor SC, Lerman A, Lerman LO. Lowenergy shockwave therapy improves ischemic kidney microcirculation. J Am Soc Nephrol 2016;27:3715-24. https://doi.org/10.1681/ASN.2015060704
  18. Jia T, Olauson H, Lindberg K, Amin R, Edvardsson K, Lindholm B, Andersson G, Wernerson A, Sabbagh Y, Schiavi S, Larsson TE. A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol 2013;14:116. https://doi.org/10.1186/1471-2369-14-116
  19. Dao M, Pouliquen C, Duquesne A, Posseme K, Mussini C, Durrbach A, Guettier C, François H, Ferlicot S. Usefulness of morphometric image analysis with Sirius Red to assess interstitial fibrosis after renal transplantation from uncontrolled circulatory death donors. Sci Rep 2020;10:6894. https://doi.org/10.1038/s41598-020-63749-3
  20. Cao S, Pan Y, Terker AS, Arroyo Ornelas JP, Wang Y, Tang J, Niu A, Kar SA, Jiang M, Luo W, Dong X, Fan X, Wang S, Wilson MH, Fogo A, Zhang MZ, Harris RC. Epidermal growth factor receptor activation is essential for kidney fibrosis devel-opment. Nat Commun 2023;14:7357.
  21. Chen QQ, Liu K, Shi N, Ma G, Wang P, Xie HM, Jin SJ, Wei TT, Yu XY, Wang Y, Zhang JY, Li P, Qi LW, Zhang L. Neuraminidase 1 promotes renal fibrosis development in male mice. Nat Commun 2023;14:1713.
  22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8. https://doi.org/10.1006/meth.2001.1262
  23. Hsiao CC, Huang WH, Cheng KH, Lee CT. Low-energy extracorporeal shock wave therapy ameliorates kidney function in diabetic nephropathy. Oxid Med Cell Longev 2019;2019:8259645. https://doi.org/10.1155/2019/8259645
  24. Ha CH, Kim S, Chung J, An SH, Kwon K. Extracorporeal shock wave stimulates expression of the angiogenic genes via mechanosensory complex in endothelial cells: mimetic effect of fluid shear stress in endothelial cells. Int J Cardiol 2013;168:4168-77. https://doi.org/10.1016/j.ijcard.2013.07.112
  25. Mazzei L, Docherty NG, Manucha W. Mediators and mechanisms of heat shock protein 70 based cytoprotection in obstructive nephropathy. Cell Stress Chaperones 2015;20:893-906. https://doi.org/10.1007/s12192-015-0622-z
  26. Hatanaka K, Ito K, Shindo T, Kagaya Y, Ogata T, Eguchi K, Kurosawa R, Shimokawa H. Molecular mechanisms of the angiogenic effects of low-energy shock wave therapy: roles of mechanotransduction. Am J Physiol Cell Physiol 2016;311:C378-85. https://doi.org/10.1152/ajpcell.00152.2016
  27. Abe Y, Ito K, Hao K, Shindo T, Ogata T, Kagaya Y, Kurosawa R, Nishimiya K, Satoh K, Miyata S, Kawakami K, Shimokawa H. Extracorporeal low-energy shock-wave therapy exerts antiinflammatory effects in a rat model of acute myocardial infarction. Circ J 2014;78:2915-25. https://doi.org/10.1253/circj.CJ-14-0230
  28. Stenvinkel P, Chertow GM, Devarajan P, Levin A, Andreoli SP, Bangalore S, Warady BA. Chronic inflammation in chronic kidney disease progression: role of Nrf2. Kidney Int Rep 2021;6: 1775-87. https://doi.org/10.1016/j.ekir.2021.04.023
  29. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979;11:447-55. https://doi.org/10.1007/BF01002772
  30. Xue Y, Xu Z, Chen H, Gan W, Chong T. Low-energy shock wave preconditioning reduces renal ischemic reperfusion injury caused by renal artery occlusion. Acta Cir Bras 2017;32:550-8. https://doi.org/10.1590/s0102-865020170070000006
  31. Steere HK, DeLuca S, Borg-Stein J, Malanga GA, Tenforde AS. A narrative review evaluating extracorporeal shockwave therapy as a potential regenerative treatment for musculoskeletal conditions in military personnel. Mil Med 2021;186:682-706. https://doi.org/10.1093/milmed/usab106
  32. Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol 2014;10:493-503. https://doi.org/10.1038/nrneph.2014.114
  33. Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov 2016;15:568-88. https://doi.org/10.1038/nrd.2016.67